These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Murine T-cell hybridomas that produce lymphokine with macrophage-activating factor activity as a constitutive product. Erickson KL; Cicurel L; Gruys E; Fidler IJ Cell Immunol; 1982 Sep; 72(1):195-201. PubMed ID: 6184172 [No Abstract] [Full Text] [Related]
26. Increased responsiveness to macrophage-activating factor (MAF) after alteration of macrophage membranes. Piessens WF; Remold HG; David JR J Immunol; 1977 Jun; 118(6):2078-82. PubMed ID: 325137 [TBL] [Abstract][Full Text] [Related]
27. Intercellular communication: role of soluble factors in cellular immune responses. Klesius PH J Am Vet Med Assoc; 1982 Nov; 181(10):1015-21. PubMed ID: 6816771 [No Abstract] [Full Text] [Related]
28. Production and characterization of antisera against guinea pig macrophage activating factor. Peck R; Talmadge K; Polak L Int Arch Allergy Appl Immunol; 1984; 75(4):361-7. PubMed ID: 6389371 [TBL] [Abstract][Full Text] [Related]
29. Down regulation of RNA labeling as a selective marker for cytotoxic but not suppressor macrophages. Varesio L J Immunol; 1984 Jun; 132(6):2683-5. PubMed ID: 6202756 [No Abstract] [Full Text] [Related]
30. The mechanism of action of lymphokines. VII. Modulation of the action of macrophage migration inhibitory factor by antioxidants and drugs affecting thromboxane synthesis. Jakubowski A; Pick E Immunopharmacology; 1983 Oct; 6(3):215-29. PubMed ID: 6313550 [TBL] [Abstract][Full Text] [Related]
31. Membrane perturbation and stimulation of arachidonic acid metabolism. Gemsa D; Leser HG; Seitz M; Deimann W; Bärlin E Mol Immunol; 1982 Oct; 19(10):1287-96. PubMed ID: 6294507 [No Abstract] [Full Text] [Related]
32. Biological control of lymphokine function. Yoshida T; Cohen S Fed Proc; 1982 Jun; 41(8):2480-3. PubMed ID: 7044831 [TBL] [Abstract][Full Text] [Related]
33. Glycolipid affinity purification of migration inhibitory factor. Liu DY; David JR; Remold HG Nature; 1982 Mar; 296(5852):78-80. PubMed ID: 7038511 [No Abstract] [Full Text] [Related]
34. The MAF dilemma. Fidler IJ Lymphokine Res; 1984; 3(2):51-4. PubMed ID: 6379318 [No Abstract] [Full Text] [Related]
40. Binding characteristics of fluoresceinated Lotus tetragonolobus fucolectin to macrophage populations which are either responsive or refractory to activation by lymphokine. Leu RW; Herriott MJ; Webb CF Immunobiology; 1985 Apr; 169(3):272-9. PubMed ID: 3888826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]